Caidya Strengthens European Growth Strategy and Appoints Mario Bautista as Head of Business Development, Europe
RALEIGH, N.C.; Feb 10, 2026 – Caidya, a leading global, mid-sized CRO focused on accelerating clinical development for innovative biopharmaceutical companies, today announced the appointment of Mario Bautista as Head of Business Development, Europe. In this role, Bautista will lead Caidya’s commercial growth strategy across the region, strengthening partnerships with innovative drug developers, supporting the efficient development of novel therapies.
Bautista brings extensive experience in clinical development, business development, and regional leadership within the CRO and life sciences services industry. Most recently, he served as Head of Southern and Eastern Europe and Early Clinical Development at IQVIA Biotech, where he led regional business development teams, oversaw commercial strategy for early clinical programs, and managed key strategic sponsor relationships across Europe.
“Mario’s deep understanding of the European biotech and biopharma landscape and his ability to translate complex clinical capabilities into clear, sponsor-focused solutions make him an exceptional addition to our leadership team,” said Brandon Pallott, Chief Commercial Officer at Caidya. “As innovative European drug developers look for agile, high-touch CRO partners, Mario will play a critical role in helping them advance their programs with confidence and speed.”
“I’m excited to join Caidya at a time when innovation across Europe’s drug development sector is accelerating,” said Bautista. “Caidya’s collaborative approach, scientific depth, and commitment to operational excellence uniquely position the company to support small and mid-sized biopharma organizations as they move from early development through pivotal milestones.”
Based in Europe, Bautista will focus on building long-term partnerships, developing regional talent, and helping sponsors bring life-changing therapies to patients faster.
About Caidya
Caidya is a global, mid-sized clinical research organization (CRO) that partners with biopharma innovators to advance breakthrough therapies for patients with unmet medical needs. Built to adapt at the speed of science, Caidya operates with a partner-first mindset, integrating seamlessly with sponsor teams and bringing ownership, transparency, and agility to complex clinical programs.
With direct presence in more than 20 countries and studies conducted across over 40 countries and regions – with distinctive capabilities in China – Caidya provides access to diverse patient populations across the Americas, Europe, and APAC. The company delivers full-service clinical development solutions, supported by deep therapeutic and operational expertise in oncology and hematology, cell and gene therapy, rare and pediatric diseases, dermatology, renal, and other specialized therapeutic areas. Through data-driven decision-making, experienced teams, and a patient-first approach, Caidya delivers high-quality execution that helps sponsors move with confidence from early development through post-approval.
MEDIA CONTACT:
Roger Boutin
VP, Corporate Marketing, Caidya